CL2012002118A1 -
Anti-cd79b antibodies; immunoconjugate of said antibody; pharmaceutical composition containing said immunoconjugate; use of said antibody to treat cancer.
- Google Patents
Anti-cd79b antibodies; immunoconjugate of said antibody; pharmaceutical composition containing said immunoconjugate; use of said antibody to treat cancer.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=52012059&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002118(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentch IncfiledCriticalGenentch Inc
Publication of CL2012002118A1publicationCriticalpatent/CL2012002118A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Anticuerpos anti-CD79B; inmunoconjugado de dicho anticuerpo; composición farmacéutica que contiene dicho inmunoconjugado; uso de dicho anticuerpo para tratar cáncer.Anti-CD79B antibodies; immunoconjugate of said antibody; pharmaceutical composition containing said immunoconjugate; use of said antibody to treat cancer.
CL2012002118A2007-07-162012-07-31
Anti-cd79b antibodies; immunoconjugate of said antibody; pharmaceutical composition containing said immunoconjugate; use of said antibody to treat cancer.
CL2012002118A1
(en)
Anti-cd79b antibodies; immunoconjugate of said antibody; pharmaceutical composition containing said immunoconjugate; use of said antibody to treat cancer.
Isolated antibody or fragment that binds to an inactive state of a her receptor; pharmaceutical composition comprising it; use of the antibody to treat cancer
ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO CD37, IMMUNOCONJUGATE COMPRISING THE SAME, USE OF THE SAID ANTIBODY, FRAGMENT AND IMMUNOCONJUGATE, COMPOSITION COMPRISING THE SAME, KIT, ISOLATED CELL, AS WELL AS IN VITRO METHOD TO INHIBIT GROWTH MENT OF A CELL THAT EXPRESSES CD37
Bispecific antibody that specifically binds to human erbb-3 and human c-met proteins; nucleic acid encoding it; pharmaceutical composition that includes it; and its use to treat cancer
ANTI-RECEIVER ANTIBODY OF INSULINAL GROWTH FACTOR I (IGF-IR); POLINUCLEOTIDE THAT CODIFIES IT; METHOD OF PRODUCTION; COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT CANCER.
Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same
Thienopyrimidine and pyrazolopyrimidine compounds, mtor kinase and pi3 kinase inhibitors; pharmaceutical composition comprising said compound; and its use to treat atherosclerosis, arthritis, cancer, among other diseases.
Binding molecule comprising an antigen-binding portion that binds to a c3b neoepitope; pharmaceutical composition comprising it; and its use to treat eye disorders
Pyrimidine derived compounds, phosphatidylinositol-3-kinase inhibitors; pharmaceutical composition comprising said compounds; and its use for the treatment of respiratory diseases, allergies, inflammation, cancer, among other diseases.
Monoclonal antibody that specifically binds human tyrp1; fragment of any of the antibodies indicated above; nucleic acid encoding antibody or fragment; expression vector; recombinant cell; use of the antibody or fragment to treat cancer.